Foundation Medicine Receives Medicare Payment in Non-Small Cell Lung Cancer under a Local Coverage Determination for FoundationOne®, the Company's Comprehensive Genomic Profiling Assay

CytomX Announces Full-Year 2016 Financial Results

Global Blood Therapeutics Announces Participation at Two Upcoming Investor Conferences in March

bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine

CytomX Therapeutics to Announce Full-Year 2016 Financial Results

Eleven Biotherapeutics to Present at Upcoming Investor Conferences in March

MyoKardia to Present at Cowen and Company 37th Annual Health Care Conference

Voyager Therapeutics Supports Rare Disease Day® and Global Movement to Raise Awareness for Rare Diseases

Jounce Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference

Foundation Medicine to Present at Cowen and Company's 37th Annual Healthcare Conference

Blueprint Medicines to Present at Upcoming Investor Conferences in March

bluebird bio to Present at Two Investor Conferences in March

Zafgen to Present at Upcoming Investor Conferences

Agios to Present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017

Editas Medicine Joins Global Movement to Raise Awareness on Rare Disease Day 2017

Editas Medicine to Present at Investor Conferences in March

Global Blood Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares

First-Ever Device for Fast and Virtually Painless Blood Draw Receives FDA Clearance

Sage Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

bluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress

Foundation Medicine Announces 2016 Fourth Quarter and Year-End Results, Recent Highlights and 2017 Outlook

Global Blood Therapeutics Prices a $125.0 Million Upsized Common Stock Public Offering

CytomX Therapeutics to Present at Upcoming Investor Conferences

Using Mono-allelic Mass Spectrometry Data to Improve Epitope Prediction Algorithms Published in Immunity

Sage Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, February 23, 2017

Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones

Sage Therapeutics Not in M&A Discussions: STATEMENT

Global Blood Therapeutics Announces Initiation of Phase 1 Trial to Evaluate the Physiologic Effects of GBT440 in Healthy Volunteers Under Hypoxemic Conditions

Rhythm Announces Completion of $41 Million Mezzanine Financing

Blueprint Medicines to Present at 2017 RBC Capital Markets Global Healthcare Conference

Editas Medicine Announces U.S. Patent and Trademark Office Decision Favorable to Broad Institute in CRISPR Interference

Ablexis Announces Perpetual License Agreement for AlivaMab Mouse with Janssen

Global Blood Therapeutics Announces Publication of Paper Describing Discovery of GBT440 in ACS Medicinal Chemistry Letters

Decibel Therapeutics Presents at 2017 Annual Association for Research in Otolaryngology (ARO) Meeting

Sage Therapeutics Advances SAGE-217 into Placebo-Controlled Phase 2 Clinical Trial in Major Depressive Disorder

Voyager Therapeutics Announces Lead Clinical Candidate Selection for Monogenic Form of Amyotrophic Lateral Sclerosis (ALS)

Editas Medicine to Present at Upcoming February Investor Conferences

Zafgen to Present at the Leerink Partners 6th Annual Global Healthcare Conference

Goldfinch Bio Appoints Nephrologist Louis Brenner, M.D., M.B.A. to Board of Directors

Eleven Biotherapeutics to Present at the 2017 BIO CEO & Investor Conference

Fulcrum Therapeutics Strengthens its Board of Directors with the Addition of Alan Ezekowitz, MBChB, D.Phil., and James J. Collins, Ph.D.

Sage Therapeutics to Participate in Upcoming February Investor Conferences

Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2016 Financial Results and Conference Call

bluebird bio Announces First Patient Treated with LentiGlobinâ„¢ Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease

CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-072 Trial

First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491

MyoKardia Announces Appointment of June Lee, M.D., as Chief Operating Officer and Radhika Tripuraneni, M.D., as Vice President, Medical Affairs

Jounce Therapeutics Announces Pricing of Initial Public Offering

Voyager Therapeutics Announces Publication of Vectored Anti-Tau Monoclonal Antibody Study in The Journal of Neuroscience

Voyager Therapeutics Announces Updates from Phase 1b Trial of VY-AADC01 for Advanced Parkinson's Disease